Best ETFs to Invest In, According to AI Analyst, 4/15/2026

Macroeconomic uncertainty and geopolitical tensions in the Middle East continue to impact investor sentiment. Given a volatile backdrop, exchange-traded funds (ETFs) could be a good investment choice, thanks to their benefits, including lower risk from diversification and lower costs. TipRanks’ ETF AI Analyst helps investors select attractive ETFs that can generate solid returns.

Claim 55% Off TipRanks

Here, we will look at three Outperform-rated ETFs with the potential to generate strong returns: Capital Group Core Equity ETF (CGUS), Fidelity Blue Chip Value ETF (FBCV), and Health Care Select Sector SPDR Fund (XLV).

Using TipRanks’ Stock Comparison Tool, let’s look at a few metrics of these ETFs.

1. Capital Group Core Equity ETF (CGUS) — The CGUS ETF offers exposure to stocks that have the potential for capital appreciation and/or dividend payments. The ETF AI Analyst has a price target of $45 on the CGUS ETF, indicating about 9% upside potential. The CGUS ETF offers a dividend yield of 0.93%. The Outperform rating on CGUS is backed by strong holdings such as Alphabet (GOOGL), Microsoft (MSFT), Nvidia (NVDA), and Apple (AAPL).
2. Fidelity Blue Chip Value ETF (FBCV) — The FBCV ETF seeks long-term growth of capital by investing in blue-chip companies. It provides exposure to stocks that are undervalued on factors such as assets, sales, and earnings, and/or undervalued relative to peers in the industry. The ETF AI Analyst has a price target of $41 on the FBCV ETF, implying about 10% upside potential. The bullish stance of the AI Analyst on FBCV is based on strong, diversified holdings such as Alphabet and Merck (MRK). It offers a dividend yield of 2.81%.
3. Health Care Select Sector SPDR Fund (XLV) — The XLV ETF tracks the Health Care Select Sector Index and provides exposure to companies in the pharmaceuticals, health care equipment and supplies, health care providers and services, biotechnology, life sciences tools and services, and health care technology industries. The ETF AI Analyst has a price target of $167 on the XLV ETF, implying about 13.30% upside potential. Additionally, the XLV ETF offers a dividend yield of 1.7%. The Outperform rating on XLV is based on major healthcare companies like Johnson & Johnson (JNJ) and Merck.